We report a new assay to measure the serum concentrations of the atypical antipsychoticdrug clozapine and two major metabolites, norclozapine and clozapine-N-oxide.
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The analytes and an internal standard (triprolidine)were extracted from alkalinized samples into ethyl acetate and back-extracted into 0.1 mauL HCI. The acid extracts were chromatographed on a reversed-phase liquid chromatographic column with photodiode array detection nm). With the 254-nm signal, between-run imprecision (CV) was <2% for clozapine and norclozapine at 400 .Lg/L,and 4.1% for clozapine-N-oxide at 100 g/L Absolute recovery exceeded 65%, and the detection limit was -3-4 g/L In 25 patients at steady state at a mean daily clozapine dosage of 269 mg (3. 09 mg/kg), clozapine averaged 231 ± 144 zg/L (mean ± SD); norclozapine and clozapine-N.oxide concentrations averaged 84% and 23% that of clozapine. Analyte concentrations were significantly correlated with daily dose. The method's ability to quantify clozapine and two major metabolites simultaneously with precision and sensitivity makes it useful in pharmacokinetic studies and therapeutic monitoring. Ui, The working solution of internal standard (300 p.gfL triprolidune) was prepared as follows: 1.0 mL of triprolidine stock calibrator diluted to 50 mL with deionized water; 15.0 mL of this intermediate solution was diluted to 100 mL with 0.4 mol/L NaOH to provide a final working solution.
Working calibrator solutions were prepared by appropriate dilution of stock calibrators with drug-free human serum to yield a solution containing clozapine and norclozapine (each at 800 pglL) and clozapine-N-oxide (at 200 pg/L). Working control solutions were prepared similarly to contain the analytes at one-half or onefourth the concentration of the working calibrator.
Procedure
Patients and sample collection. Twenty-five patients received a constant daily dose of clozapine of 269 ± 129 mg (3.09 ± 1.59 mg/kg body wt, mean ± SD) for at least 4 weeks before sample collection. In addition to clozapine, the use of benzodiazepines, antidepressants, lithium, and other medically indicated agents was permitted. Patients taking other agents known to alter drug metabolism, such as cimetidine, fluoxetine, phenytoin, and valproic acid, were excluded. Eight patients were women and 17 were men, mean ± SD ages of 41.0 ± 6.6 and 33.8 ± 8.1 years, respectively. Samples were obtained immediately before a first daily dose of clozapine, at 12-20 (15.5 ± 2.0) h since the last dose. Blood samples were drawn into red-topped evacuated tubes without additives, allowed to clot at room temperature for 15-30 mm, and then centrifuged at 1000 x g for 10 mm. The serum was transferred into polypropylene tubes and frozen at -20 #{176}C until analysis, usually within 4 weeks.
Sample preparation.
We added 600 L of serum, 100 jiL of working internal standard, and 7 mL of ethyl acetate to a 16 x 100 mm acid-washed screw-cap glass tube, vortex-mixed for 1 mi centrifuged at 1000 x g for 10 mm, and transferred the ethyl acetate phase to another tube containing 150 iL of 0.1 moIIL HC1. This mixture was vortex-mixed for 1 miii and then centrifuged, and 50 L of the aqueous phase was injected into the chromatograph.
Analyte quantification.
To quantify the analytes, we used the peak height ratio of the analyte to the internal standard (at 254 nm) and compared this ratio with that obtained for a working calibrator solution. The identity of all analyte peaks in a sample was confirmed by matching the ultraviolet spectra from 210 to 340 nm (or, in the case of norclozapine, from 240 to 340 nm) to the spectrum of a standard contained in the PDA library.
Results and Discussion data also are shown in Table 1 : the between-run imprecision (CV) ranged from 1.6% to 5.8%. The analytes were stable for at least 3 months in serum stored at -20 #{176}C, for 2 weeks in mobile phase at room temperature, and for at least 3 days in 0.1 moIJL HC1 at room temperature.
Representative chromatogranis at 254 nm are shown in Figure 1 . The Spherisorb C6 column used was reported by Jatlow and Nadim (13) to chromatograph several basic drugs efficiently. All columns used exhib- loxapine provides adequate assay precision despite a lower absolute recovery than triprolidine.
We do not use loxapine routinely because it coelutes with one of the later-eluting suspected clozapine metabolites (peak 7).
In addition to PDA detection, we tested for interferencesby chromatographing >200 drugs or their metabolites; 21 eluted within ± 0.1 mm of the analytes. When serum-based solutions of these 21 compounds were processed through the entire extraction and chromatographic procedure, only 9 compounds exhibited potential interference. We tested 1000 p.gfL serum standards of these nine compounds and estimated the interference they might cause at 254 Using detection wavelengths <240 rim increased the chance of interference to the analytes and greatly increased the height of the "solvent front" complex, making measurement of norclozapine problematic. Detection in the 240-260-nm range gave greater assay sensitivity than did the longer wavelengths. Peaks representing analyte serum concentrations of 3-4 j.t.gfL were distinguishable from system "noise." The PDA did not detect interferences in the samples studied. In one sample we observed a peak that was not fully resolved from norclozapine; its spectrum was imilnr to that of peaks 5 and 7 in Figure 1 . No interconversion of the analytes was observed in analyses of serum-based standards containing only one analyte. 12.4-191) . Even though dosing in this study was determined clinically and was not con- trolled, significant correlations were found between analyte concentrations and the daily dose (mg/kg) of clozapine (see Table 2 ). Norciozapine concentrations in the In that report clozapine averaged 374 ± 227 pg/L (range 84-1088 gfL), and norclozapine was 116 ± 62 ugfL (range 25-272 j.gIL). Thus, despite generally higher doses and serum clozapine concentrations than the present study, lower norciozapine concentrations were found. Note, however, that in all three of these studies just reviewed the ratio of serum clozapine concentration to daily dose was very similar [0.859, 0.928 (6), and 0.974 (14) ]. The present assay is among the most sensitive reported for these analytes, and its precision is superior to that of the previously reported LC or GC methods. Its ability to measure several clozapine metabolites simultaneously makes it useful in pharmacokinetic studies and therapeutic drug monitoring. 
